Boehringer Ingelheim GmbH and Eli Lilly and Company have won a second indication for their jointly developed diabetes drug Jardiance (empagliflozin) which belongs to a new class of drugs known as sodium glucose transporter 2 (SGLT2) inhibitors. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
